OssiGel: the formation of human mini-bones as personalized drug-testing platform

Important results from the project

Many cancers emerge or ultimately develop in our bones, including acute myeloid leukemia. Current treatments show poor success rates, calling for more relevant models. To address this, OssiGel is proposed as a technology for generating human mini-bones (ossicles) using patient cells, enabling better cancer models and personalized drug testing. In this project, the objectives lie in demonstrating the formation of patient ossicles using OssiGel, and validating them for in vivo drug testing in the context of AML.

Expected long term effects

OssiGel was demonstrated to offer the reliable formation of patient mini-bones. Proof-of-concept was also achieved regarding their use as a drug-testing platform. Further assessment will allow validating the use of OssiGel as a more personalized thus predictive model for the treatment of acute myeloid leukemia. These results will steer the development of OssiGel as a product.

Approach and implementation

The Vinnova support in this project was instrumental for the validation of OssiGel as a valuable technology for the cancer field. The generated data confirm the potential of our technology as a superior drug-testing platform. A start-up company is now planned to be develop around the OssiGel technology.